Friday, 16 October 2026European Markets

SAINT JEAN GROUPE Stock Impressive Fall 10% So Far On Tuesday, Underperforms Market

Loading stream...

saint jean groupe's (cac 40: sabe.pa) shares experienced an extreme drop of 10.45% to eur19.70 after two consecutive sessions of gains. this occurred despite an uptick in cac 40 of just 0.226% to eur7,443.88, partially offsetting its previous session's drop.

share performance

saint jean groupe closed at eur22.40 last friday, representing no change from its 52-week high of eur26.00 and with its 52-week low standing at eur16.90. at eur0.18, this company's trailing twelve-month earnings per share are relatively modest. this produces an astronomically high price to earnings ratio - 109.44 in fact - meaning investors would have to shell out eur109.44 in order to purchase just one euro of annual earnings.

company's financial status

the return on equity over this same time frame stands at only 0.81%. saint jean groupe saw its highest average intraday variation over the last week at 4.31%, 3.11% over the past month and 2.78% for the last quarter. saint jean groupe's stock dropped today; however, its value still exceeds both its 50-day moving average of eur19.14 and 200-day moving average of eur18.71.

market trends

in fact, today's results demonstrate how far higher its current share price is than its 52-week low, further strengthening an optimistic outlook for saint jean groupe. however, today's traded volume for saint jean groupe was considerably below average compared to its typical volume of 170 shares changing hands each day. this could indicate decreasing investor enthusiasm about investing in this company despite its attractive p/e ratio.

investment considerations

based on these financial indicators, potential investors should carefully assess the return on equity and p/e ratio, taking into account recent share price drops and increased volatility.

more news about saint jean groupe (sabe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com